Skip to main content
S. 150 118th Congress Senate

Affordable Prescriptions for Patients Act of 2023

Official title: A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.

Introduced: January 30, 2023 Introduced by: John Cornyn Republican · Texas See on congress.gov
Health Administrative remediesCivil actions and liabilityCompetition and antitrustConsumer affairs
More subjectsShow fewer subjects
Drug safety, medical device, and laboratory regulationFederal Trade Commission (FTC)Health care costs and insuranceInflation and pricesIntellectual propertyJudicial review and appealsManufacturingPrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 11 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 15, 2024
Held at the desk.
Jul 15, 2024
Received in the House.
Jul 12, 2024
Message on Senate action sent to the House.
Jul 11, 2024
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S4537-4538)
Jul 11, 2024
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Jul 11, 2024
Measure laid before Senate by unanimous consent. (consideration: CR S4537-4538)
Mar 1, 2023
Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.
Mar 1, 2023
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Feb 9, 2023
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Jan 30, 2023
Read twice and referred to the Committee on the Judiciary.
Jan 30, 2023
Introduced in Senate
 Amendments to this bill 1

Amendments propose changes to this bill. Members vote on amendments separately before the final bill vote. An agreed amendment becomes part of the bill; a failed amendment does not.

1 agreed to

AmendmentSponsorPurposeStatusLatest action
SAMDT 2,399 Cornyn, John In the nature of a substitute. Agreed to Jul 11, 2024
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action July 15, 2024

Held at the desk.

 Plain-English summary Congressional Research Service

Affordable Prescriptions for Patients Act of 2023

This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version.

Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.

 

 

 Bill text 3 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 22

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

  • NOVO NORDISK INC.
    for NOVO NORDISK INC. · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
  • NOVO NORDISK INC.
    for NOVO NORDISK INC. · District of Columbia · 2nd Quarter 2026 (Apr 1 - June 30)
  • NOVO NORDISK INC.
    for NOVO NORDISK INC. · District of Columbia · 1st Quarter 2026 (Jan 1 - Mar 31)
  • NOVO NORDISK INC.
    for NOVO NORDISK INC. · District of Columbia · 4th Quarter 2025 (Oct 1 - Dec 31)
  • BLUECROSS BLUESHIELD OF TENNESSEE
    for BLUECROSS BLUESHIELD OF TENNESSEE · Tennessee · 4th Quarter 2025 (Oct 1 - Dec 31)
  • NOVO NORDISK INC.
    for NOVO NORDISK INC. · District of Columbia · 3rd Quarter 2025 (July 1 - Sep 30)

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 22 filings →
 Cosponsors 7
All 7 Democratic 4 Republican 3
R
Murkowski, Lisa
Alaska · Apr 9, 2024
 D
Welch, Peter
Vermont · May 2, 2023
 D
Blumenthal, Richard
Connecticut · Jan 30, 2023
 R
Cruz, Ted
Texas · Jan 30, 2023
 D
Durbin, Richard J.
Illinois · Jan 30, 2023
 R
Grassley, Chuck
Iowa · Jan 30, 2023
 D
Klobuchar, Amy
Minnesota · Jan 30, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). S. 150: Affordable Prescriptions for Patients Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-150/
MLA
"S. 150: Affordable Prescriptions for Patients Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-150/.
Bluebook (legal)
S. 150, 118th Cong. (2026), https://openamerica.io/bill/118-S-150/.
Markdown link
[S. 150: Affordable Prescriptions for Patients Act of 2023](https://openamerica.io/bill/118-S-150/)
Report a problem